Premature closure of the trial greatly curtailed the power of the study to detect an effect on HIV (23 events provided only ∼40% power to detect a 50% reduction in risk).
Therefore, we anticipate that each individual surgeon will only operate on 2 3 patients enrolled in the trial, greatly reducing the risk of a surgeon-specific effect on the outcome at any one centre.
The care provided in the usual care arm of trials varied greatly (Table 1).
The outcome of these trials is greatly anticipated because they have the potential of changing the current standards of care in the adjuvant treatment of patients with breast cancer.
Adding a genetic component to treatment trials could greatly help to understand the biological basis of variations in the efficacy of therapies and, in the future, could lead to individualized choices of therapy.
Contrary to the wide experience with this strategy in cancer, in HIV-1 infection the experience is limited and the design of the clinical trials varies greatly between groups.
It is also suggested by the related phenomenon of spike-time reliability, in which the reproducibility of a single neuron's output spike train across trials is greatly enhanced by a fluctuating input when compared to a constant input [16, 17].
Enrollment in clinical trials was greatly enhanced by the development of the multidisciplinary clinic.
Utilizing pharmacodynamic biomarkers to optimize drug dose and scheduling in these trials could greatly enhance the likelihood of clinical success.
